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Recent advances in basic research and
clinical trials have poisedmotor and visual
prostheses to help restore movement and
sight. Together with cochlear implants
and deep brain stimulators already in
use for improving audition and reducing
tremor, neural prostheses offer a new
avenue of therapy. Progress will continue
to depend on deeper scientific under-
standing of the underlying neural circuits
and how they process information. One
limitation to sustained progress relates
to the inability to measure activity from
millions of identified neurons simulta-
neously. New methods are needed, as
highlighted by President Obama’s BRAIN
Initiative. Less appreciated is the critical
need for new conceptual frameworks for
information processing. Without these,
it is unclear whether the ‘‘big data’’
produced by new measurements will
result in deeper scientific understanding.
Emerging frameworks include those
based on dynamical systems, dimension-
ality reduction, recurrent neural networks,
and machine learning and should in-
crease the performance of prostheses.
Another limitation relates to ‘‘writing’’ in-
formation into the brain. While optoge-
netics has revolutionized neuroscience
by enabling the modulation of cell-type-
specific and projection-targeted neurons,
the ability to create naturalistic patterns of
activity acrossmillions of specific neurons
is still needed. Altering neural activity in
this way (along various ‘‘meaningful di-
mensions’’) should allow neural prosthe-
ses to deliver better sensory signals.Deconstructing Disease and
Treatment
Helen Mayberg
Emory University
Catalyzed by 20 years of advances in
neuroimaging methods, there has been a
fundamental shift in the biological con-
structs of neuropsychiatric disorders, with
a growing emphasis on systems-level net-
work models. Highlighting this paradigm
shift is deep brain stimulation: focal modu-
lation of specific neural circuits using im-
planted electrodes that is being applied to
a growing number of intractable conditions
such as depression. While efficacy testing
of deep brain stimulation for any particu-
lar disorder will likely continue through
conventional clinical trials, the unique
potential to simultaneously deconstruct
disease pathophysiology and treatment
mechanisms through these studies is an
opportunity we cannot afford to miss. To
understand, optimize, and improve these
emerging treatment strategies, we can
directly leverage next-generation tools
using complementary and synergetic
human and animal studies. In patients, we
can now track immediate, short-term, and
long-term cellular changes in real time at
the site of stimulation, complementing
studies using structural and functional
imaging (PET, EEG, DTI, MRI). Such
approaches provide critical foundation for
explicit reverse-translational experiments
in animals with multiunit electrophysiolog-
ical recordings in relevant neural circuits
using homologous stimulation targets and
parameters. Truly bidirectional studies
between patients and animals should
streamline progress across research fields
and ultimately improve treatments. But,
such progress can only occur in an envi-
ronment that facilitates well-funded multi-
disciplinary team science.Cell 156,Toward Selectivity and
Refinement
Peter Brown
University of Oxford
Think of your central heating being on all
of the time, winter or summer. Now
imagine the fuel supplied to be the same
for every house, big or small. That is the
state of current electrical brain stimulation
therapies in Parkinson’s disease. Patients
undergo fixed, continuous, regular high-
frequency stimulation of key brain targets
through an implanted pacemaker irre-
spective of their current state. Just as
modern central heating tracks tempera-
ture using a thermostat, we should
identify the core brain circuit changes
underpinning symptoms and continually
monitor these to optimally control
stimulation. Understanding these circuit
changesmay also tell us withwhat pattern
to best stimulate for any given symptom
complex. We are just beginning to under-
stand the aberrant circuit dynamics in
Parkinson’s disease sufficiently well to
explore such closed loop and intelligently
patterned stimulation regimes. But we
must also make stimulation more selec-
tive in space. Electrodes with finer
resolution and steerable fields are in
development, and the ultimate in cell-
type-specific control is potentially achiev-
able through techniques like optogenetics
and pharmacogenetics. There are, how-
ever, major obstacles to be overcome
before cell-type-specific treatments can
be realized in patients. Meanwhile, electri-
cal stimulation represents a tractable
means by which to interact with brain cir-
cuits that can still be substantially im-
proved, with significant near-term gains
for patients.February 27, 2014 ª2014 Elsevier Inc. 861
Therapy for the Periphery
Scott Delp
Stanford University
The power of optogenetics to improve our
understanding of neural circuits is clear.
Applying optogenetic techniques to hu-
mans, however, remains a goal that is
yet to be realized. In my laboratory, we
have used optogenetics to manipulate
activity in selected neurons of the periph-
eral nervous system, motivated by the
desire to use optogenetics to excite mus-
cle in cases of paralysis, inhibit motor
neurons to reduce spasticity, and control
nociceptors to treat neuropathic pain.
Others have demonstrated that optoge-
netics can be applied to control neuronal
activity in nonhuman primates or have
used optogenetics in rodent models to
partially restore vision. Translating these
exciting results into optogenetic therapies
for humans will require successfully over-
coming a set of challenges. These include
the identification of important disease
states that are not adequately addressed
by electrical stimulation, pharmacology,
or other therapies, demonstration of a
potent therapeutic effect of optogenetics
in an animal model of the disease state,
development and demonstration of safe
and effective gene therapy techniques
that can transduce selected neurons in
humans, development and evaluation of
devices to deliver light to transduced neu-
rons in humans, and, finally, management
of a clinical trial to evaluate the safety and
efficacy of the optogenetic treatment.
Meeting these challenges will be difficult
but will allow us to harness the power of
optogenetics to improve human health.862 Cell 156, February 27, 2014 ª2014 ElsevProstheses in Sight
Sheila Nirenberg
Cornell University
New technologies come along every few
years. Sometimes they are a fad, and
sometimes they let us move forward in
big leaps. Here, I’d like to give an example
about how a specific technology—opto-
genetics—made a real leap possible.
The example involves a treatment we’re
developing for restoring sight for patients
with retinal degenerative diseases. Pa-
tients with these diseases need a way to
get visual information to their brains.
This is a two-step process. First, the infor-
mation needs to be converted into the
retina’s neural code. Second, the code
needs to be transmitted to the brain. My
lab works on neural coding and had
addressed the first step: converting visual
images of arbitrary complexity such as
faces and landscapes in real time into
the retina’s code. But how could we get
the coded signals to the brain? Electrodes
don’t offer a good solution because
they’re too coarse: the retina’s code has
single-cell resolution, and electrodes
would force us to blur this as each elec-
trode stimulates 50–100 cells. This is
where optogenetics came in: the resolu-
tion it provides matches the resolution of
the code, and when we put the two
together, we had a very effective solution.
We converted the solution into a pros-
thetic system that can make completely
blind retinas in animals behave very
much like normal ones, and we’re now
starting to bring it through the FDA and
into clinical trials.ier Inc.Coping with Background Noise
Vincent Walsh
UCL
I’ve just read about Google’s acquisi-
tion of DeepMind, and I was impressed,
but not surprised, at the humility of
Demis Hassabis, the founder of the
$400,000,000 AI company. He empha-
sizes how difficult it is to understand the
human brain. This is in stark contrast to
my own field, human brain stimulation.
There are many claims, based on small
effects under laboratory conditions, that
brain stimulation can improve memory,
mathematical cognition, creativity, lan-
guage, or performance in athletes or
military personnel. In some cases, there
seems to be a lack of understanding of
the conceptual and technical gulf be-
tween these lab results and what to
expect in the real-world setting. Over-
blown statements also don’t help. Human
brain stimulation has proven its worth in
the treatment of depression and neurode-
generative disorders, but success in other
fields has so far been limited. There are
dangers in not being grounded in reality;
for those who can’t see these patterns,
I’d recommend Carl Djerassi’s novel
‘‘Cantor’s Dilemma’’ as a good fictional-
ization of the issues and the cost of not
confronting them. The success of trans-
cranial magnetic stimulation in depres-
sion shows that brain stimulation can
make a serious contribution to health,
and it may be the case that other forms
of stimulation will be useful for other con-
ditions. But, unless we take a step back
now, we are in danger of spreading false
hope and of masking real potential in the
low signal-to-noise environment created
by shouting before there is much to say.
Ear and Brain
Robert V. Shannon
USC
Recent outcomes with auditory prosthe-
ses present a unique opportunity for un-
derstanding brain mechanisms of speech
and music. Both cochlear implants and
auditory brainstem implants provide ex-
cellent speech recognition but poor
music recognition. The outcomes across
patients are highly variable, ranging from
no speech recognition to the ability to
converse by telephone. Children born
deaf have shown variable degrees
of speech recognition with a cochlear
implant. These differences across the
types of implants—sound type (speech
vs. music), previous sound experience
(congenital vs. acquired), and develop-
mental age (adult vs. child)—offer unique
opportunities for understanding cortical
mechanisms for processing auditory pat-
terns. Recent advances in brain imaging
and connectivity will allow us to track the
changes in brain pathways that occur
when adults learn to adapt to a distorted
pattern of neural information provided by
auditory prosthesis. We will also be able
to track the development of auditory
pattern recognition in congenitally deaf
children and to understand differences in
brain processing between patients with
good and poor outcomes. Such new
knowledge should provide insight on
how the brain adapts to new or distorted
patterns of sensory information. The com-
bination of new prostheses and new
imaging provides leverage toward better
understanding the dynamic synergy be-
tween ear and brain.Cell 156, February 27, 2014 ª2014 Elsevier Inc. 863
